Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
HGV driver recruited others to smuggle migrants - 2How to watch ‘The Traitors’ U.K. Season 4 premiere today from the U.S.
- 3Flying without a Real ID? That'll soon cost you $45, TSA says.
- 4Figure out How to Get the Best Open Record Rewards
- 5The Craft of Do-It-Yourself Home Stylistic layout: Change Your Space
- Scientists document a death from a meat allergy tied to certain ticks
- Vacation destinations in America
- Vote In favor of Your Number one Kind Of Food Conveyance Administration
- Flight cancellations: Full list of 40 airports hit by FAA cuts amid government shutdown
- Israeli military says it hit dozens of military facilities in Tehran
- NASA satellite gazes into Medusa Pool | Space photo of the day for Dec. 24, 2025
- First Houthi launch toward Israel since war began triggers alerts across the Negev
- Sa'ar warns German delegation: 'A Palestinian state would be a Hamas terror state'
- Benihana is 60 years old. Gen Z is lining up.
